AHCYL2

Across TCGA pan-cancer cohorts, AHCYL2 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of AHCYL2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where AHCYL2 RNA is repressed in tumor relative to normal tissue. In most cancer types AHCYL2 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

COAD, THCA, and KIRC are the cancer types where AHCYL2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AHCYL2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	IV	−3.125	<.001	12	view →
THCA	Male	III,IV	−1.950	<.001	10	view →
KIRC	All	II,III,IV	−0.737	<.001	10	view →
LUSC	Female	II,III,IV	−2.822	<.001	8	view →
KICH	Male	All	+1.369	<.001	7	view →
LIHC	Female	All	+0.712	<.001	7	view →
KIRP	Male	All	−0.644	.008	6	view →
READ	All	II,III,IV	−3.255	<.001	5	view →
CHOL	All	All	+1.121	.001	5	view →
LUAD	All	All	−0.562	.004	3	view →
PAAD	Male	All	+1.255	.014	2	view →
STAD	Male	IV	−1.210	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

AHCYL2–COAD

Open the COAD breakdown →